Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SG Holding's Haiki+ offer draws 510,764 shares by end of second week

SG Holding's Haiki+ offer draws 510,764 shares by end of second week

BitgetBitget2026/10/16 16:27
  • SG Holding's offer for Haiki+ drew 235,332 shares during October 12–16, 2026, bringing total tenders to 510,764 shares.
  • Including tendered shares, SG Holding and parties acting in concert reached 91,610,861 shares, representing 70.97% of capital.
  • Sostenya Group bought 109,355 shares outside the offer at EUR 0.90 each on October 16.
  • The EUR 0.90-per-share offer aims to acquire the entire share capital and delist the company from Euronext Growth Milan.
  • The offer closes November 6, with payment scheduled for November 13, unless extended.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haiki+ S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20334_172779_2026_oneinfo.pdf), on October 16, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss